Dr Keith Menear CChem FRSC

Keith Menear is a Fellow of the Royal Society of Chemistry and has over 28 years experience in the pharmaceutical sector as a Medicinal Chemist, Project Leader and Senior Manager. He started his career within global pharmaceuticals at Ciba-Geigy (eventually to become Novartis) working in the UK and Switzerland.

After 14 years as a Project Leader and Manager he moved into the biotechnology sector and joined KuDOS Pharmaceuticals as Director of Chemistry. It was here that he lead the chemistry team in the discovery of 4 clinical candidates including Lynparza (olaparib) recently granted regulatory approval and the first drug taken into clinical trials that demonstrated the concept of “Synthetic Lethality” in a BRCA genetic background. In addition to Olaparib Keith steered the development of the mTOR inhibitors AZD2014 (Phase II) and AZD8055 (Phase I) that are currently in clinical trials. He was part of the management team at KuDOS Pharmaceuticals that in 2006 realised the trade sale of the company to AstraZeneca.

In 2008 Keith established Menear Consulting Ltd and has worked to support a number of companies in the global pharma, biotech and the charity sectors.

Keith is also a Scientific Founder of MISSION Therapeutics and CAMPHOS Therapeutics.